Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05192200 · ClinicalTrials.gov registry record · Phase 2
An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study
A Phase 2 study of Dermatomyositis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 20
- Study locations
NCT05192200: Completed Phase 2 study of Dermatomyositis, sponsored by Pfizer.
NCT05192200 is a Phase 2 study of Dermatomyositis that has completed, run by Pfizer. The registered enrollment target is 24 participants, below the 484-participant average among 19 other Dermatomyositis trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05192200, a Phase 2 study of Dermatomyositis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this research study is to evaluate the long-term safety, and tolerability of PF-06823859 study drug in adult participants with Dermatomyositis (DM) from a qualifying study.
Primary Outcome
An Adverse Event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered treatment emergent relative to a given treatment if the event occurred for the first time during the effective duration of treatment and was not seen prior to the start of treatment, or the event was seen prior to the start of treatment but increased in
Conditions Studied
Interventions
- DRUG Anti-Beta Interferon (PF-06823859)
Study Locations (20)
New York
- NYU Grossman School of Medicine, The Ronald O. Perelman Department of Dermatology - New York
- NYU Langone Health Clinical Research Center - New York
- NYU Langone Radiology - Ambulatory Care Center East 41st Street - New York
- Mount Sinai Doctors Dermatology - New York
- Icahn School of Medicine at Mount Sinai - New York
Kansas
- KU Clinical Research Center - Clinical and Translational Science Unit (CTSU) - Fairway
- KU Clinical and Translational Science Unit (CTSU) Rainbow - Kansas City
- University of Kansas Medical Center - Kansas City
Missouri
- Center for Outpatient Health - St Louis
- Washington University School of Medicine - St Louis
- Washington University School of Medicine - St Louis
Alabama
- University of Alabama at Birmingham - Birmingham
- University of Alabama at Birmingham, Department of Dermatology - Birmingham
Massachusetts
- Brigham & Women's Hospital - Boston
- Brigham and Women's Hospital - CTH - Boston
Arizona
- Mayo Clinic - Scottsdale
California
- Attune Health Research Inc. - Beverly Hills
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-12-20 |
| Est. Completion | 2023-11-20 |
| Phase | Phase 2 |
What the finished NCT05192200 record still lists
NCT05192200 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 484-participant average among 19 other Dermatomyositis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Dermatomyositis appearing as the primary indexed condition, and to 1 intervention - of which Anti-Beta Interferon (PF-06823859) is the first listed.
NCT05192200 names 20 study sites across 10 states, led by New York, Kansas, Missouri.
Frequently Asked Questions
What is clinical trial NCT05192200 about?
NCT05192200 is a clinical study titled "An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study". The purpose of this research study is to evaluate the long-term safety, and tolerability of PF-06823859 study drug in adult participants with Dermatomyositis (DM) from a qualifying study.
What is the current status of trial NCT05192200?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2021-12-20. Estimated completion is 2023-11-20.
What conditions does trial NCT05192200 study?
This clinical trial studies the following conditions: Dermatomyositis.
What interventions are being tested in trial NCT05192200?
The interventions under investigation include: Anti-Beta Interferon (PF-06823859) (DRUG).
Who is sponsoring clinical trial NCT05192200?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05192200 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatomyositis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05192200's enrollment target sits among peer trials
24 15th of 19 higher than 5 of 19 other Dermatomyositis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dermatomyositis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RECRUITING · Phase 2
-
Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
RECRUITING · Phase 2
-
Intralesional Injection of STS in Treatment of Calcinosis
RECRUITING · Phase 2
-
A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI